TearClear Raises $22MM to Advance Multiple Clinical Programs in Development

TearClear announces appointment of Stuart Raetzman to Board of Directors

Boston, MA, US, Aug 11, 2020 — 

TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Participating in the raise was Visionary Ventures, Bluestem Capital and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology.

The company also announces the appointment of Stuart Raetzman, who most recently served as Chief Executive Officer of Galderma, to the TearClear Board of Directors. “Stuart is a life science industry executive with proven success in pharmaceuticals, biologics, medical devices and over‐the‐counter products. His appointment further strengthens our Board and his commercial expertise will be a tremendous value to the team” said TearClear Chief Executive Officer, Robert Dempsey.

Read the rest of the press release here on TearClear's website or view a PDF archive of the story here.

Shared by Tyler Stowater, board member of TearClear Corp.